Surprisingly, bio is pretty similar to software capital-wise, at least initially and the standard YC deal works well. Jared and Jorge wrote good pieces around t

Surprisingly, bio is pretty similar to software capital-wise, at least initially and the standard YC deal works well. Jared and Jorge wrote good pieces around this recently - https://blog.ycombinator.com/how-biotech-startup-funding-will-change-in-the-next-10-years/ https://blog.ycombinator.com/how-biotech-startup-funding-wil... https://techcrunch.com/2019/08/09/biotech-researchers-venture-into-the-wild-to-start-their-own-business/ https://techcrunch.com/2019/08/09/biotech-researchers-ventur... Case in point - Asher Bio from the most recent YC batch went from zero to a working molecule & in-vivo data in ~3 months on the standard deal - https://techcrunch.com/2019/08/20/here-are-the-82-startups-that-launched-on-day-2-of-ycs-s19-demo-days/ https://techcrunch.com/2019/08/20/here-are-the-82-startups-t...